Braveheart Bio priced its initial public offering at $382 million, the largest biotech IPO in sixteen months and the anchor of a week that saw $847 million flow into four new biotech listings. The company develops myosin inhibitors for obstructive hypertrophic cardiomyopathy, a genetic heart condition affecting roughly one in 500 adults. It went public with Phase 2 data already in hand.
The offering priced at $18 per share, the midpoint of the range, moving 21.2 million shares. First-day trading lifted the stock 11.7% to close at $20.11, giving Braveheart a post-money valuation of $1.47 billion. Lead underwriters were Goldman Sachs and JPMorgan, with eight additional bookrunners including Jefferies and Leerink Partners. The company's lead asset, BRVE-101, is a next-generation cardiac myosin inhibitor designed to reduce left ventricular outflow obstruction without the liver enzyme warnings that dogged earlier entrants in the category.
The raise marks a sharp reversal from 2023 and 2024, when biotech IPO windows slammed shut and only a handful of companies with late-stage or pivotal trial readouts could access public capital. Braveheart is the sixth U.S. biotech IPO in 2026 and the first to clear $300 million since a neurology play raised $410 million in April 2025. Family offices and crossover funds that sat out early-stage biotech for two years are now writing checks again — but only if Phase 2 data exists. Of the six biotech IPOs this year, five had at least interim mid-stage efficacy data at pricing. The sixth had orphan-drug designation and a breakthrough therapy designation from FDA.
Braveheart's BRVE-101 competes directly with Bristol-Myers Squibb's Camzyos, which posted $578 million in sales last quarter and is on track for $2.4 billion in 2026 revenue. The total addressable market for symptomatic obstructive HCM is estimated at $6.7 billion annually in the U.S. and Europe, with room for multiple entrants if differentiation on safety or dosing convenience is clear. Braveheart's Phase 2b trial enrolled 214 patients across 38 sites and hit its primary endpoint: mean reduction in peak left ventricular outflow gradient of 43 mmHg at twelve weeks, with 78% of patients achieving gradients below 30 mmHg. No hepatotoxicity signals appeared in the dataset, a clean edge over first-generation myosin inhibitors.
The $382 million in proceeds funds two parallel Phase 3 trials, each enrolling 400 patients, with topline data expected in Q3 2028. Braveheart will also initiate a 150-patient Phase 2 study in non-obstructive HCM, a larger and less-served population, by Q1 2027. Cash runway extends into mid-2029, past the Phase 3 readouts. The company's pre-IPO investors include Arch Venture Partners, Versant Ventures, and Cormorant Asset Management, none of whom sold shares in the offering. The lockup expires in 180 days.
Allocators should watch three catalysts in the next eighteen months: enrollment completion of the first Phase 3 trial by Q2 2027, interim safety data from the non-obstructive study in Q4 2027, and any partnership or co-development discussions with large cardio-focused pharma, likely telegraphed through executive hires or board additions. If BRVE-101 holds its safety profile through Phase 3, Braveheart becomes an acquisition candidate for any top-ten pharma company rebuilding its cardiovascular franchise.
The biotech IPO window is open, but it is not indiscriminate. Four more venture-backed biotechs have confidentially filed S-1s in the past six weeks. All four have at least Phase 2 data.
The takeaway
Biotech IPOs are back, but only with mid-stage data — preclinical pitches remain shut out for now.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.